Anifrolumab - Bristol-Myers Squibb/MedImmune

Drug Profile

Anifrolumab - Bristol-Myers Squibb/MedImmune

Alternative Names: Anti-IFNaR MAb - Bristol-Myers Squibb/MedImmune; MDX-1333; MEDI-546

Latest Information Update: 29 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medarex
  • Developer Medarex; Medical University of Vienna; MedImmune
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interferon alpha beta receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Systemic lupus erythematosus
  • Phase II Lupus nephritis; Rheumatoid arthritis
  • Discontinued Scleroderma

Most Recent Events

  • 18 Jul 2018 MedImmune completes a phase II trial in Systemic lupus erythematosus in USA, Brazil, Bulgaria, Colombia, Czech Republic, Hungary, Mexico, Peru, Poland, Romania, South Korea, Taiwan and Ukraine (NCT01753193) (EudraCT2012-004619-30)
  • 17 Jul 2018 AstraZeneca completes a phase III trial for Systemic lupus erythematosus in USA, UK, Argentina, Australia, Brazil, Chile, Colombia, Germany, Hungary, Israel, Italy, South Korea, New Zealand, Peru, Poland, Romania, Taiwan and Ukraine (NCT02446912)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top